Roche’s sales recover in Brazil in Q3’20, continue growth in Mexico


  • 1602821518106
  • Argentina,Brazil,Cuba,Colombia,Chile,Puerto Rico ,Costa Rica,Panama,Peru,Paraguay,Uruguay,Venezuela,Ecuador ,Dominican Republic,Guyana,Bolivia ,Mexico,Haiti,Guatemala,Honduras,El Salvador,Belize,Nicaragua
  • Company
  • Pharma & Biotech, Device & Diagnostics

Swiss major Roche Holding AG (SWX.RO)’s Q3 2020 financial results reveal the firm stabilized its performance amid the ongoing COVID-19 outbreak. Worldwide group sales over the first nine months were up 1% year-on-year (YOY) in constant currency terms to CHF 43.97 billion (USD 48.09 billion), a return to growth following the Q2 -4% dip. The pharmaceutical division sales were down -1% to CHF 34.31 billion (USD 37.53 billion), while the diagnostics business expanded by +9% YOY to CHF 9.66 billion (USD 10.57 billion), with COVID-19 testing the main contributor.

Roche’s pharmaceutical division now faces severe biosimilars competition around the world against cancer stalwarts Herceptin (trastuzumab), Avastin (bevacizumab), and MabThera (rituximab), which together made up 31% of global sales during the year to date (YTD), down from 42% at the same time in 2019. COVID-19 disruptions have also impacted the ability of patients to access Roche's specialist drug portfolio. New products launched since 2012 provided some compensation with 35% growth, accounting for 40% of YTD sales, from only 29% in 2019. Key new drugs for the firm are the programmed death-ligand 1 (PD-L1) inhibitor Tecentriq (azetolizumab), multiple sclerosis therapy Ocrevus (ocrelizumab), hemophilia treatment Hemlibra (emicizumab), and the Herceptin replacement Perjeta (pertuzumab). GBI analysis shows that these products are all present in Latin America.

Pharmaceutical sales in Brazil recovered from the 24% YOY plunge in Q2 2020, expanding 1% to CHF 219 million (USD 240 million) in Q3, while the Mexico market continued its positive trend growing 8% to CHF 71 million (USD 78 million). Similarly, Q3 diagnostics sales regained impetus in Brazil increasing 18% to CHF 74 million (USD 81 million) from the 25% drop in Q2, while turnover in Mexico reached CHF 49 million (USD 54 million) in Q3, up 36%.

Roche also reports an ongoing Phase II clinical trial (CT) in Colombia evaluating humanized monoclonal antibody (mAb) crenezumab (RG7412) against Alzheimer’s disease.

Reference:

Related news
According to GBI analysis, Chile's Institute of Public Health (ISP) this week published the approvals of US firm Pfizer’s biosimilar Ruxience (rituximab), Netherlands-based Synthon’s Gatrel (sunitinib), a first-in-market generic version of Pfizer’s Sutent, as well as Argentina-based Varifarma’s Nibclus (ponatinib), a first-mover generic of Pint Pharma’s Iclusig.
China-based biotech Shanghai Henlius Biotech Inc., (HKEX.2696) announced a market approval filing for a new 60mg specification of Hanquyou (trastuzumab; HLX02), the firm's biosimilar version of Roche’s breast and stomach cancer medicine Herceptin.
Swiss major Roche Holding AG (SWX.RO)’s Q3 2020 financial results reveals the firm's performance stabilized amid the ongoing COVID-19 outbreak.
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA:600196; HKG:02196) announced a licensing agreement between its subsidiary Shanghai Henlius Pharmaceutical Co., Ltd (HKEX.02696) and compatriot firm Essex Bio-Technology Co., Ltd, in relation to HLX04, Henlius's biosimilar version of the Roche-originated Avastin (bevacizumab).
China-based biotech Innovent Biologics Inc., (HKEX.01801) picked up its fourth product approval in China, announcing the National Medical Products Administration (NMPA) nod for the firm’s Halpryza (rituximab), a biosimilar version of Roche’s MabThera.
Recent news
Mexican authorities last week revealed that the SARS-CoV-2 vaccine advanced purchases that were announced recently will include 51 million doses from the World Health Organization (WHO)’s COVAX initiative, up to 34 million of Pfizer’s double-dose immunization, 77 million of AstraZeneca (AZ)’s double-dose vaccine, and 35 million of CanSino’s single-dose treatment, totalling 197 million doses for 116.7 million people.
According to GBI analysis, Chile's Institute of Public Health (ISP) this week published the approvals of US firm Pfizer’s biosimilar Ruxience (rituximab), Netherlands-based Synthon’s Gatrel (sunitinib), a first-in-market generic version of Pfizer’s Sutent, as well as Argentina-based Varifarma’s Nibclus (ponatinib), a first-mover generic of Pint Pharma’s Iclusig.
Brazil’s Ministry of Science, Technology, Innovation and Communication (MCTIC) this week announced results of a clinical trial (CT) evaluating the efficacy of broad-range antiviral nitazoxanide against early-stage COVID-19.
Óscar Vicente Scavone, president of Paraguay-based Laboratorios Éticos, last week commented on the local pharmaceutical industry’s situation and prospects amid the COVID-19 pandemic.
Russian bank and financial services giant Sberbank and compatriot pharma firm JSC Pharmasyntez signed a cooperation agreement on October 14, 2020.
The National Healthcare Security Administration (NHSA) released a notification in relation to the diagnosis-related group (DRG)-style payment pilot work plan, including plans to roll out an “index/points” system that will enable DRG.
China food delivery giant Meituan struck up a strategic partnership with Germany-based giant Bayer’s Consumer Health Division in China.
Analytics Snapshot


Analytics Snapshot